Adcytherix (NASDAQ: ADTX) Initiates Phase 1 Trial of ADCX-020 and Enhances Leadership Team

March 31, 2026

Market Overview Adcytherix (NASDAQ: ADTX) has taken a significant step in advancing its oncology pipeline with the dosing of the first patient in its Phase 1 clinical trial for ADCX-020. This milestone marks the company’s continued commitment to developing innovative antibody-drug conjugates aimed at addressing unmet needs in cancer treatment. Following this development, ADTX stock has drawn interest from investors focusing on biopharmaceutical innovation. The launch of the trial positions…

Read More >>